GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (FRA:31R) » Definitions » Net Interest Income

Revive Therapeutics (FRA:31R) Net Interest Income : €0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Revive Therapeutics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Revive Therapeutics's net interest income for the three months ended in Mar. 2025 was €-0.00 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Revive Therapeutics Net Interest Income Historical Data

The historical data trend for Revive Therapeutics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Net Interest Income Chart

Revive Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 0.01 0.04 0.05 0.03

Revive Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Revive Therapeutics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revive Therapeutics Net Interest Income Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Revive Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (FRA:31R) » Definitions » Net Interest Income
Comparable Companies
XCNQ:PWR TSX:AVNT XCNQ:BBM TSX:CTX XCNQ:MVMD XCNQ:SE XCNQ:CLC TSXV:CANB XCNQ:AYUR TSXV:PCLO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
RVVTF:USA RVV:Canada
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Website
https://www.revivethera.com
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

Revive Therapeutics Headlines

No Headlines